title: ERK regulates the hepatocyte growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase.
abstract: Based on our previous observations that active ERK associates with and phosphorylates Gab1 in response to HGF, and the prediction that the ERK phosphorylation site is adjacent to one of the phosphatidylinositol 3-kinase (PI3K) SH2 binding motifs, we examined the possibility that ERK phosphorylation can regulate the Gab1/PI3K association. The HGF-mediated association of Gab1 with either full-length GST-p85 or its isolated N- or C-terminal SH2 domains was inhibited by approximately 50% in the setting of ERK inhibition, a result confirmed by co-immunoprecipitation of the native proteins. A 14-amino acid peptide encoding (472)YVPMTP(477) (one of the major p85 binding sites in Gab1 and the predicted ERK phosphorylation site) was synthesized with either phosphotyrosine alone (pY), or phosphotyrosine + phosphothreonine (pYT). In both pull-down assays and competition assays, pYT demonstrated a higher affinity for p85 than did pY alone. Finally, examination of the phosphorylation state of Akt after HGF stimulation revealed that ERK inhibition resulted in a decrease in Akt activation at both 5 and 10 min. These results suggest that activated ERK can phosphorylate Gab1 in response to HGF stimulation and thereby potentiate the Gab1/PI3K association and subsequent PI3K activation.
authors.affiliation: Department of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut 06520-8062, USA. chengfang.yu@yale.edu
authors.forename: C F
authors.initials: CF
authors.lastname: Yu
authors.forename: B
authors.initials: B
authors.lastname: Roshan
authors.forename: Z X
authors.initials: ZX
authors.lastname: Liu
authors.forename: L G
authors.initials: LG
authors.lastname: Cantley
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D002070:Butadienes / Q000494:pharmacology; D002460:Cell Line; D016895:Culture Media, Serum-Free; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism*; D017228:Hepatocyte Growth Factor / Q000494:pharmacology*; D007700:Kinetics; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D009570:Nitriles / Q000494:pharmacology; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D010748:Phosphopeptides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism; D010750:Phosphoproteins / Q000737:chemistry / Q000378:metabolism*; D010769:Phosphothreonine; D019000:Phosphotyrosine; D021122:Protein Subunits; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000378:metabolism; D018909:src Homology Domains
chemical_list: D002070:Butadienes; D016895:Culture Media, Serum-Free; D004791:Enzyme Inhibitors; D009570:Nitriles; D010446:Peptide Fragments; D010748:Phosphopeptides; D010750:Phosphoproteins; D021122:Protein Subunits; D011993:Recombinant Fusion Proteins; C113580:U 0126; D010769:Phosphothreonine; D019000:Phosphotyrosine; D017228:Hepatocyte Growth Factor; D019869:Phosphatidylinositol 3-Kinases; D020928:Mitogen-Activated Protein Kinases